Disclosure of interest: Elisabeth Hofstaetter: Medical Lead of Novartis Pharma GmbH, All other authors: nothing to disclose Poster Session I - RISK FACTORS - PRIMARY AND SECONDAR PREVENTION 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.02 - SECONDARY PREVENTION P389 - ESOC25-2231 ADDRESSING GENDER DISPARITIES IN CEREBROVASCULAR CLINICAL TRIALS: BARRIERS AND STRATEGIES FOR INCLUSION Virginia Cancelloni 1 , Victoria Rcker 2 , Kirsten Harvey 3 , Kirsten Haas 2 , Peter Heuschmann 2 , Bianca Koehler 1 , Mara Graziani 1 , Roland Veltkamp 3,4 , Valeria Caso 1 1 Stroke Unit and Division of Cardiovascular Medicine, University of Perugia, Perugia, Italy, 2 Institute of Clinical Epidemiology and Biometry, University of Wrzburg, Wrzburg, Germany, 3 Department of Brain Sciences, Imperial College London, London, United Kingdom, 4 Department of Neurology, Alfried Krupp Krankenhaus Essen, Essen, Germany Background and Aims: The underrepresentation of women in cerebrovascular randomised control trials (RCTs) remains a pressing issue
Calverley P, Rogliani P, Papi A
Int J Womens Health 4:543549 Malloy KM, Wang J, Clark LH, Fang Z, Sun W, Yin Y, Kong W, Zhou C, Bae-Jump VL (2018) Novasoy and genistein inhibit endometrial cancer cell proliferation through disruption of the AKT/mTOR and MAPK signaling pathways
Antioxidants, 13 (4), 394
